Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 1
2004 2
2005 2
2006 6
2007 5
2008 2
2009 3
2010 3
2011 5
2012 4
2013 6
2014 13
2015 7
2016 6
2017 13
2018 10
2019 8
2020 13
2021 18
2022 14
2023 14
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Results by year

Filters applied: . Clear all
Page 1
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
Rodriguez-Otero P, Usmani S, Cohen AD, van de Donk NWCJ, Leleu X, Pérez-Larraya JG, Manier S, Nooka AK, Mateos MV, Einsele H, Minnema M, Cavo M, Derman BA, Puig N, Gay F, Ho PJ, Chng WJ, Kastritis E, Gahrton G, Weisel K, Nagarajan C, Schjesvold F, Mikhael J, Costa L, Raje NS, Zamagni E, Hájek R, Weinhold N, Yong K, Ye JC, Sidhana S, Merlini G, Martin T, Lin Y, Chari A, Popat R, Kaufman JL; International Myeloma Working Group. Rodriguez-Otero P, et al. Among authors: zamagni e. Lancet Oncol. 2024 May;25(5):e205-e216. doi: 10.1016/S1470-2045(24)00043-3. Lancet Oncol. 2024. PMID: 38697166 Review.
Outcomes of Modified Mayo Stage IIIa and IIIb Cardiac Light-Chain Amyloidosis: Real-World Experience in Clinical Characteristics and Treatment-67 Patients Multicenter Analysis.
Charliński G, Steinhardt M, Rasche L, Gonzalez-Calle V, Peña C, Parmar H, Wiśniewska-Piąty K, Dávila Valls J, Olszewska-Szopa M, Usnarska-Zubkiewicz L, Gozzetti A, Ciofini S, Gentile M, Zamagni E, Kurlapski M, Legieć W, Vesole DH, Jurczyszyn A. Charliński G, et al. Among authors: zamagni e. Cancers (Basel). 2024 Apr 21;16(8):1592. doi: 10.3390/cancers16081592. Cancers (Basel). 2024. PMID: 38672674 Free PMC article.
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients.
Borsi E, Vigliotta I, Poletti A, Mazzocchetti G, Solli V, Zazzeroni L, Martello M, Armuzzi S, Taurisano B, Kanapari A, Pistis I, Zamagni E, Pantani L, Rocchi S, Mancuso K, Tacchetti P, Rizzello I, Rizzi S, Dan E, Sinigaglia B, Cavo M, Terragna C. Borsi E, et al. Among authors: zamagni e. Cells. 2024 Apr 9;13(8):657. doi: 10.3390/cells13080657. Cells. 2024. PMID: 38667272 Free PMC article.
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma.
Mateos MV, Weisel K, Terpos E, Delimpasi S, Kastritis E, Zamagni E, Delforge M, Ocio E, Katodritou E, Gay F, Larocca A, Leleu X, Otero PR, Schjesvold F, Cavo M, Dimopoulos MA. Mateos MV, et al. Among authors: zamagni e. Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.284694. Online ahead of print. Haematologica. 2024. PMID: 38385280 Free article.
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features.
Terragna C, Poletti A, Solli V, Martello M, Zamagni E, Pantani L, Borsi E, Vigliotta I, Mazzocchetti G, Armuzzi S, Taurisano B, Testoni N, Marzocchi G, Kanapari A, Pistis I, Tacchetti P, Mancuso K, Rocchi S, Rizzello I, Cavo M. Terragna C, et al. Among authors: zamagni e. Nat Commun. 2024 Feb 20;15(1):1551. doi: 10.1038/s41467-024-45000-z. Nat Commun. 2024. PMID: 38378709 Free PMC article.
Real-world treatment patterns in patients initiating third-line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain.
Lehne M, Kortüm KM, Ramasamy K, Zamagni E, d'Estrubé T, Zhuleku E, Hanna M, Shukla S, Ghiani M, Maywald U, Wilke T, Kellermann L, Perera S. Lehne M, et al. Among authors: zamagni e. Eur J Haematol. 2024 May;112(5):701-713. doi: 10.1111/ejh.14161. Epub 2023 Dec 25. Eur J Haematol. 2024. PMID: 38146208
Multidisciplinary Management of Sternal Osteomyelitis Due to Klebsiella aerogenes after Open Heart Surgery in a Patient with Multiple Myeloma: A Case Report and Discussion of the Literature.
Pignatti M, Dolci G, Zamagni E, Pascale R, Piccin O, Ammar A, Zeneli F, Miralles MEL, Mancuso K, Cipriani R, Viale P, Pacini D, Martin-Suàrez S. Pignatti M, et al. Among authors: zamagni e. Microorganisms. 2023 Nov 3;11(11):2699. doi: 10.3390/microorganisms11112699. Microorganisms. 2023. PMID: 38004712 Free PMC article.
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients.
Borsi E, Mazzocchetti G, Dico AF, Vigliotta I, Martello M, Poletti A, Solli V, Armuzzi S, Taurisano B, Kanapari A, Pistis I, Zamagni E, Tacchetti P, Pantani L, Mancuso K, Rocchi S, Rizzello I, Cavo M, Terragna C. Borsi E, et al. Among authors: zamagni e. Clin Exp Med. 2023 Dec;23(8):5227-5239. doi: 10.1007/s10238-023-01205-y. Epub 2023 Oct 10. Clin Exp Med. 2023. PMID: 37815734 Free PMC article.
147 results